NEW YORK (CNNMoney.com) -- The FDA will decide soon whether Wyeth’s experimental drug for schizophrenia merits approval for the U.S. market.The Food and Drug Administration is expected to make a decision as early as Friday regarding the schizophrenia drug bifeprunox, developed by Wyeth (up $1.21 to $50.55, Charts, Fortune 500) and its partner, Solvay Pharmaceuticals.
